Skip to main content

Lee Yuchun's Form 4 filing

Vertex Pharmaceuticals Inc (VRTX) · filed Apr 20, 2022

Accession no.
0000899243-22-015163
Filed
Apr 20, 2022
Trade date
Apr 18, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $568.5K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lee YuchunCIK 0001334365Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 18, 2022Common StockMOption exerciseAcquired+2,000$81.54+$163,0803,875Direct
Apr 18, 2022Common StockSSaleDisposed−382$282.70F2,F3−$107,991.43,493Direct
Apr 18, 2022Common StockSSaleDisposed−1,008$284.06F2,F4−$286,332.482,485Direct
Apr 18, 2022Common StockSSaleDisposed−491$285.16F2,F5−$140,013.561,994Direct
Apr 18, 2022Common StockSSaleDisposed−119$286.80F2,F6−$34,129.21,875Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 18, 2022Common StockMOption exerciseDisposed−2,000$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Referenced by the price of 4 transactions in Table I.

F3

Open market sales reported on this line occurred at a weighted average price of $282.70 (range $282.40 to $283.15).

Referenced by the price of 1 transaction in Table I.

F4

Open market sales reported on this line occurred at a weighted average price of $284.06 (range $283.72 to $284.46).

Referenced by the price of 1 transaction in Table I.

F5

Open market sales reported on this line occurred at a weighted average price of $285.16 (range $284.88 to $285.63).

Referenced by the price of 1 transaction in Table I.

F6

Open market sales reported on this line occurred at a weighted average price of $286.80 (range $286.68 to $286.82).

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)